TSXV:VXL - Post Discussion
Post by
knoxt on Mar 07, 2022 12:26pm
Up date on news
| Vaxil Bio Provides Update on Research Activities |
|
11:42 AM EST, 03/07/2022 (MT Newswires) -- Vaxil Bio (VXL.V) on Monday provided an update on its research activities. The company had previously reported therapeutic success of P-Esbp-DOX, a novel anti-cancer drug, when tested in vivo in a mouse model of aggressive liver metastasis of colorectal cancer (CRC). Following the promising results of the in vivo study, Vaxil is implementing a screening process of contract development and manufacturing companies to develop P-Esbp-DOX for use in a first in-human clinical trial. Last year, Vaxil conducted an initial in vivo oral vaccine study for a COVID-19 signal peptide-derived product. Following the identification of an initial signal, Vaxil decided to try to transition from the ImMucin (MUC1 signal peptide-derived product) injectable platform to an oral delivery platform. An ImMucin oral formulation was developed, and an in vivo study was performed aimed at testing the ImMucin oral formulation to induce a systemic immune response in mice. The results, have been inconclusive, and Vaxil will not pursue this. Vaxil is also exploring the value in conducting experiments of the oral formulation of the potential COVID-19 vaccine candidate in combination with mRNA vaccines to boost T-cell protection to future variants. |
Be the first to comment on this post